2018
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research 2018, 24: 4845-4853. PMID: 29941483, PMCID: PMC6168417, DOI: 10.1158/1078-0432.ccr-18-0864.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsAntineoplastic AgentsApoptosisAurora Kinase AAurora Kinase BAzepinesCell Line, TumorCell ProliferationCystadenocarcinoma, SerousDose-Response Relationship, DrugEndometrial NeoplasmsExome SequencingFemaleGene Expression Regulation, NeoplasticHumansMiceMiddle AgedPhosphorylationPrimary Cell CultureProteinsProto-Oncogene Proteins c-mycTriazolesUterine NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous carcinomaPrimary USC cell linesUSC cell linesC-myc expressionCell linesC-MycChemotherapy-resistant diseaseQRT-PCRHigh c-myc expressionDose-dependent decreaseDose-dependent increasePotential therapeutic targetEffective therapeutic agentMouse xenograft modelClin Cancer ResFresh frozen tumor tissueC-myc gene amplificationUSC xenograftsEndometrial cancerAggressive variantSerous carcinomaWhole-exome sequencing studiesClinical studiesConcentrations/dosesXenograft model
2011
Downregulation of Filamin A Interacting Protein 1-Like is Associated with Promoter Methylation and Induces an Invasive Phenotype in Ovarian Cancer
Burton ER, Gaffar A, Lee SJ, Adeshuko F, Whitney KD, Chung JY, Hewitt SM, Huang GS, Goldberg GL, Libutti SK, Kwon M. Downregulation of Filamin A Interacting Protein 1-Like is Associated with Promoter Methylation and Induces an Invasive Phenotype in Ovarian Cancer. Molecular Cancer Research 2011, 9: 1126-1138. PMID: 21693594, PMCID: PMC3157597, DOI: 10.1158/1541-7786.mcr-11-0162.Peer-Reviewed Original ResearchMeSH KeywordsCarrier ProteinsCell LineCell Line, TumorCell MovementCell ProliferationCpG IslandsCyclic AMP Response Element-Binding ProteinCytoskeletal ProteinsDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessNeoplasm StagingOvarian NeoplasmsPhenotypePromoter Regions, GeneticConceptsOvarian cancer cellsFILIP1L expressionOvarian cancerCAMP-responsive element binding proteinCancer cellsClinical ovarian cancer specimensFive-year survival rateMore effective therapeutic interventionsInvasive phenotypeLethal gynecologic malignancyOvarian cancer cell linesNormal ovarian epithelial cellsOvarian cancer specimensOvarian cancer invasionOvarian cancer therapyEffective therapeutic interventionsCell linesOvarian epithelial cellsOvarian cell linesCancer cell linesGynecologic malignanciesOvarian specimensCancer specimensStage IIIDNA demethylating agent